Search clinical trials for: Bioabsorbable polymer

Total 1816 results

Population Health Research Institute
Canadian Institutes of Health Research (CIHR); Boston Scientific Corporation

Active, not recruiting

Colchicine and Spironolactone in Patients With MI / SYNERGY Stent Registry (CLEAR SYNERGY)

ST Elevation Myocardial Infarction | Non ST Elevation Myocardial Infarction

Canada
Biotronik, Inc.

Active, not recruiting

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (BIOFLOW-VII)

Myocardial Ischemia | Coronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Ischemic Heart Disease | Atherosclerosis, Coronary

United States
Translumina GmbH
EVAMED

Active, not recruiting

Observatory to Assess the Yukon Choice PC & the Yukon Chrome PC Sirolimus Eluting Bioabsorbable Polymer Stents Systems (YuChooSeR)

Coronaropathy

France
Gangnam Severance Hospital

Active, not recruiting

Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent

Coronary Artery Disease

Korea, Republic of
Biotronik, Inc.
Medstar Health Research Institute; Biotronik AG; Baim Institute for Clinical...

Completed

Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions (BIOFLOW-V)

Myocardial Ischemia | Coronary Artery Disease | Angina Pectoris | Acute Coronary Syndrome | Ischemic Heart Disease | Atherosclerosis, Coronary

Belgium, Israel, Spain, Korea, Republic of, United States, Switzerland, Germany, Canada, Netherlands, Hungary, Denmark, New Zealand, Australia
University of Freiburg

Completed

SWiss Evaluation of Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent

Coronary Artery Disease

Switzerland
The Hospital District of Satakunta

Unknown

Comparison of Titanium-Nitride-Oxide Coated Bio-Active-Stent (Optimax™) to the Drug (Everolimus) -Eluting Stent (Synergy™) in Acute Coronary Syndrome (TIDES-ACS)

Myocardial Infarction | Atherosclerosis | Percutaneous Coronary Intervention

Finland
Azienda Ospedaliero Universitaria Maggiore della...

Unknown

Single Long vs Two Short Overlapping Bioabsorbable Polymer DES (ROCCO)

Coronary Artery Disease

Italy
Azienda Ospedaliero Universitaria Maggiore della...

Completed

Bioabsorbable Versus Durable Polymer Drug Eluting Stent (DES): a Meta-analysis

Myocardial Infarction | Restenosis

Italy
The First Hospital of Jilin University

Not yet recruiting

Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer

Platinum-sensitive Relapsed Ovarian Cancer
Australasian Gastro-Intestinal Trials Group
AstraZeneca; Wayne Elphinstone Research Fund

Not yet recruiting

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

Cholangiocarcinoma

Australia
Anhui Provincial Hospital

Recruiting

Effect of Letermovir Prophylaxis on CMV-specific Immune Reconstitution Post UCBT

Cytomegalovirus Infection Reactivation

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Not yet recruiting

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Ovarian Cancer

United States, Germany
Louisiana State University Health Sciences Center...

Recruiting

Investigation Of Bioabsorbable Screws In Pediatric Orthopedic Surgery

Patient Satisfaction | Fracture | Pediatric | Orthopedic Devices Associated With Misadventures, Surgical Instruments, Materials and Devices (Including Sutures)

United States
University of Cologne
AstraZeneca

Not yet recruiting

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE)

Small Cell Lung Carcinoma
University of Miami
GlaxoSmithKline

Not yet recruiting

Study Evaluating Safety, Tolerability, and Metabolism of Niraparib

Ovarian Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Endometrial Carcinoma | Recurrent or Metastatic | TP53 Mutation

China
Konstantinos Toutouzas
Université Catholique de Louvain; University of Patras; Centre Hospitalier Universitaire... and other collaborators

Not yet recruiting

3rd Generation Resorbable Magnesium Scaffolds vs Biodegradable Polymer Stents in NSTE/ACS

Coronary Artery Disease | Acute Coronary Syndrome

Belgium, Switzerland, Greece
University of Wisconsin, Madison
Merck Sharp & Dohme LLC

Not yet recruiting

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Kidney Transplant Infection | Cytomegalovirus Infections | Pancreas Transplant

United States
Qian Qin
Janssen, LP; UT Southwestern Comprehensive Cancer Center

Not yet recruiting

Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations (HARMONY)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | CHEK2 Gene Mutation | FANCA Gene Mutation | RAD51B Gene Mutation | RAD54L Gene Mutation | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Deleterious HRR Gene Mutation
Ivy Brain Tumor Center
GlaxoSmithKline

Not yet recruiting

A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

Glioblastoma | Brain Tumor | GBM | Brain Neoplasms, Adult, Malignant
The First Affiliated Hospital of Xiamen University

Recruiting

Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) (SEGNO)

Oligometastatic Prostate Cancer | Locally Advanced Prostate Cancer

China
Vall d'Hebron Institute of Oncology

Recruiting

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) (STROBE)

Ovarian Cancer

Spain
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma | HNSCC | Head Cancer Neck
Ibrahim Halil Sahin
GlaxoSmithKline

Not yet recruiting

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

MMR-D/MSI-H Colorectal Cancers

United States
Teleflex

Not yet recruiting

AE05ML Device for ML Hem-o-lok Polymer Clip Delivery in Laparoscopic Surgical Procedures Observational Registery Study (AE05ML)

Bile Duct Diseases | Acute Cholecystitis | Liver | Gall Bladder Disease | Prostate | Kidney | Appendix | Spleen Disease
Sun Jing

Not yet recruiting

A Clinical Study on the Efficacy and Safety of Paclitaxel Polymer Micelles and Cisplatin Combined With Cadonilimab as a Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Locally Advanced Esophageal Squamous Cell Carcinoma
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Prostatic Neoplasms, Castration-Resistant

Israel, Taiwan, Australia
Virginia Commonwealth University

Not yet recruiting

Resin Polymer (NuSmile BioFlx) Compared to Stainless Steel Crowns (3M ESPE) for Restoration of Primary Molar Teeth

Dental Caries | Tooth Decay

United States
Hospital do Rim e Hipertensão

Not yet recruiting

Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection

CMV Infection
University of Southern California
National Cancer Institute (NCI)

Recruiting

FID-007 Followed by Standard of Care Surgery in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections (LUCY-1)

Cytomegalovirus Infection

France
Fulgent Pharma LLC.

Recruiting

FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

United States
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Rohan Garje
Janssen Scientific Affairs, LLC

Not yet recruiting

177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer (LUNAAR)

Castration-resistant Prostate Cancer | Metastatic Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
University College, London
Novartis; Cancer Research UK; Janssen Pharmaceutica NV

Not yet recruiting

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)

Prostate Cancer Metastatic
Cao Weijie

Recruiting

Observational Clinical Study of Letermovir for Preventing CMV Infection After Allo-HSCT

Letemovir for the Prevention of CMV Infection After Allo-HSCT

China
Sun Yat-sen University

Recruiting

TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo

Recruiting

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (ICARUSBREAST02)

Advanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast Carcinoma

France
Armando Santoro, MD
GlaxoSmithKline; Istituto Clinico Humanitas

Not yet recruiting

Niraparib and Temozolomide in Patients Glioblastoma (ONC-2022-001)

Glioma, Malignant

Italy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Breast Cancer

China
Zhejiang Cancer Hospital
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Not yet recruiting

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Female Breast Cancer Patients | Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | HRD Positive Advanced Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC (NeoADAPT)

Triple Negative Breast Cancer

United States
Korea University Anam Hospital
Takeda; Korean Cancer Study Group

Not yet recruiting

Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency

Efficacy
Karolinska Institutet
Stockholm University

Recruiting

Acrylamide and Health Outcomes

Myocardial Infarction | Parkinson Disease | Dementia | Dementia Alzheimers

Sweden
Fox Chase Cancer Center

Recruiting

Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition

Primary Myelofibrosis | Polycythemia Vera | Chronic Myelomonocytic Leukemia | Essential Thrombocytosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Fundación EPIC

Recruiting

Plan to Evaluate Early Endothelialization of a Polymer Free Sirolimus-eluting Coronary Stent System (VIVO ISARTM) Compared With Everolimus-eluting Durable Polymer Stent (XIENCE SkypointTM) in Patients Undergoing Percutaneous Coronary Intervention.

Coronary Artery Disease

Spain
Sichuan University

Recruiting

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung Cancer | Extensive-stage Small-cell Lung Cancer

China
University of Maryland, Baltimore
Janssen Scientific Affairs, LLC

Recruiting

High-Risk Metachronous Oligometastatic Prostate Cancer Trial (KNIGHTS)

Prostate Cancer | Oligometastatic Disease

United States
Peking University People's Hospital

Recruiting

Assessment of Measurable Residual Disease in Allo-HSCT Using Digital Polymerase Chain Reaction

Acute Leukemia | MDS | CML | MDS/MPN

China

Search clinical trials for: Bioabsorbable polymer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Turkmenistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations